摘要
DPP-Ⅳ抑制剂是治疗糖尿病药物中的重要品种,市场竞争激烈。本研究调研分析了国际知名仿制药企业TEVA公司在DPP-Ⅳ抑制剂的全球专利布局、欧洲授权专利异议及申诉程序、简化新药申请(ANDA)、美国专利诉讼等相关信息,进而深入剖析TEVA制药的DPP-Ⅳ抑制剂市场化策略,为我国仿制药企业的立项和研发提供有益的实证参考。
DPP-Ⅳ inhibitors are very important drugs in the treatment of diabetes,and the market is highly competitive. In this review,information about global patent distribution,EPO opposition-appeal process,abbreviated new drug application（ ANDA） and the US patent litigation of TEVA pharmaceuticals in DPP-Ⅳ inhibitors,were searched,and the market-oriented strategy of TEVA on the DPP-Ⅳ inhibitors were comprehensively analyzed,which will provide references for Chinese generic drug companies.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2017年第17期1985-1988,共4页
Chinese Journal of New Drugs
关键词
DPP-Ⅳ
TEVA公司
仿制药
专利
诉讼
简化新药申请
异议
DPP-Ⅳ
TEVA pharmaceuticals
generic drugs
patent
litigation
abbreviated new drug application（ANDA）
opposition
